FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 05:25:40 13/06/2024 pm IST | ||
| 6.37 EUR / 6.46 EUR | +2.48% |
|
| Current month | -15.75% | ||
| 1 month | -31.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 13/24/13 | 6.35 | +1.44% |
| 12/24/12 | 6.26 | +3.64% |
| 11/24/11 | 6.04 | +0.33% |
| 10/24/10 | 6.02 | +1.01% |
| 07/24/07 | 5.96 | -1.00% |
Delayed Quote Börse Stuttgart
Last update June 13, 2024 at 01:54 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG09F1 |
| ISIN | DE000MG09F12 |
| Date issued | 14/03/2024 |
| Strike | 634.4 $ |
| Maturity | Unlimited |
| Parity | 23.41 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.95 € |
|---|---|
| Lowest since issue | 5.82 € |
| Spread | 0.09 € |
| Spread % | 1.39% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475.8
USD
Average target price
463.4
USD
Spread / Average Target
-2.60%
- Stock Market
- Certificates
- Certificat
